PepBank has no study results for Oxyntomodulin (human) yet. Data as of 2026-10-30.
Searches 0 results and 0 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Oxyntomodulin is a 37-residue peptide cleaved from human pro-glucagon (UniProt P01275, residues 53-89). It contains the full glucagon sequence (residues 53-81) followed by the octapeptide KRNRNNIA. It is described as a dual agonist at the GLP-1 receptor and the glucagon receptor, and KEGG classes mazdutide as an oxyntomodulin analog. It is not an approved medicine; it has been given by infusion in phase 1 mechanistic studies.
| Target | Action | Evidence |
|---|---|---|
| Glucagon-like peptide 1 receptorGLP1RP43220 (opens in a new tab) | Agonist | primary literatureSource (opens in a new tab) |
| Glucagon receptorGCGRP47871 (opens in a new tab) | Agonist | primary literatureSource (opens in a new tab) |
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
37 amino acids
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
pI 10.44 · Net charge at pH 7.4: 3.05
Point or use arrow keys
Henderson-Hasselbalch, EMBOSS pKa set. Calculated, not measured.
| pH | Net charge |
|---|---|
| 0 | 8.00 |
| 1 | 7.99 |
| 2 | 7.94 |
| 3 | 7.46 |
| 4 | 5.61 |
| 5 | 4.23 |
| 6 | 3.78 |
| 7 | 3.22 |
| 8 | 2.81 |
| 9 | 2.11 |
| 10 | 0.87 |
| 11 | −1.12 |
| 12 | −2.82 |
| 13 | −5.02 |
| 14 | −5.88 |
37 residues. Each residue counts in one class; F and W count as aromatic.
Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from RCSB PDB.
Oxyntomodulin (human) has 37 residues. A full-atom drawing is hard to read at this size; the sequence view is the reference.
SMILES fromPubChem CID 121494088(opens in a new tab)
CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)NAn ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.
Eisenberg consensus (normalized) scale · + K, R · − D, E
Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.
| Position | Residue | Angle | Eisenberg consensus (normalized) |
|---|---|---|---|
| 1 | H | 0° | -0.40 |
| 2 | S | 100° | -0.18 |
| 3 | Q | 200° | -0.85 |
| 4 | G | 300° | 0.48 |
| 5 | T | 40° | -0.05 |
| 6 | F | 140° | 1.19 |
| 7 | T | 240° | -0.05 |
| 8 | S | 340° | -0.18 |
| 9 | D | 80° | -0.90 |
| 10 | Y | 180° | 0.26 |
| 11 | S | 280° | -0.18 |
| 12 | K | 20° | -1.50 |
| 13 | Y | 120° | 0.26 |
| 14 | L | 220° | 1.06 |
| 15 | D | 320° | -0.90 |
| 16 | S | 60° | -0.18 |
| 17 | R | 160° | -2.53 |
| 18 | R | 260° | -2.53 |
| 19 | A | 0° | 0.62 |
| 20 | Q | 100° | -0.85 |
| 21 | D | 200° | -0.90 |
| 22 | F | 300° | 1.19 |
| 23 | V | 40° | 1.08 |
| 24 | Q | 140° | -0.85 |
| 25 | W | 240° | 0.81 |
| 26 | L | 340° | 1.06 |
| 27 | M | 80° | 0.64 |
| 28 | N | 180° | -0.78 |
| 29 | T | 280° | -0.05 |
| 30 | K | 20° | -1.50 |
| 31 | R | 120° | -2.53 |
| 32 | N | 220° | -0.78 |
| 33 | R | 320° | -2.53 |
| 34 | N | 60° | -0.78 |
| 35 | N | 160° | -0.78 |
| 36 | I | 260° | 1.38 |
| 37 | A | 0° | 0.62 |
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
No paper with results is linked to this peptide.
Counts are exact and come from studies that gave the peptide.
Studies by year
No study has results about Oxyntomodulin (human) yet.
No study with a publication year is linked to this peptide.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
2 trials match. Highest phase first. Data from ClinicalTrials.gov.
2 trials · 2 completed · 1 with posted results
A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED)
NCT01055340Apr 2010 to Jun 2010
Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)
NCT01373450Jun 2011 to Jul 2011
2 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Merck Sharp & Dohme LLCn = 12Jun 2011 to Jul 2011
Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLCn = 12Apr 2010 to Jun 2010
Obesity
Studies on this peptide. Some have results. The others have none yet.
0 studies match. Retracted studies are left out.
No study matches these filters.
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA | openFDA Drugs@FDA returned no application with oxyntomodulin as active ingredient. | 8 Oct 2026 | Not recorded |
| EU | EMA | No entry in EMA medicines data. | 8 Oct 2026 | Not recorded |
| Sport | WADA | Not named on the List; S0 may still apply (no approval anywhere) S0 bans any substance that has no approval for human use. Oxyntomodulin (human) has no approval in the sources used, so S0 may apply although the List does not name it. | 2026 List | wada-ama.org (opens in a new tab) |
Reported effects from study results.
No study results yet
The doses that these studies used. They are not recommendations.
No dose was reported in the study results.
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https://Evidence summary for Oxyntomodulin (human): counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
Outcome groups with study results, by evidence class.
No study results yet
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
No study results yet
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.
Trials by phase
2 registered trials, grouped by phase and shown by status.
Source: ClinicalTrials.gov, data version 308560. Status is the registry status.